维普中文期刊产品整合服务
6篇 您的检索式:作者名="LEFENG ZHANG"
    题名 作者 年代 出处 被引量
1Platelet function monitoring guided antiplatelet therapy in patients receiving high-risk coronary interventions显示文摘Xu Li Wang Lefeng Yang Xinchun Li Kuibao Sun Hao Zhang Dapeng Wang Hongshi Li Weiming Ni Zhuhua Xia Kun Liu Yu 2014Chinese Medical Journal2014,,19:8
2Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial显示文摘Zhang Yaojun Chen Fang Takashi Muramatsu Xu Bo Li Zhanquan Ge Junbo He Qing Yang Zhijian Li Shumei Wang Lefeng Wang Haichang He Ben Li Kang Qi Guoxian Li Tianchang Zeng Hesong Peng Jianjun Jiang Tieming Zeng Qiutang Zhu Jianhua Fu Guosheng Christos V. Bourantas Patrick W. Serruys Huo Yong 2014Chinese Medical Journal2014,,11:8
3Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial显示文摘Yuan Fei Chen Xin Song Xiantao Wang Dongqi Zhang Zheng Li Weimin Li Zhanquan Li Hui Chen Xinyi Huo Yong Wang Lefeng Lu Caiyi Lu Qinghua Xu Bo Li Wei Lyu Shuzheng 2014Chinese Medical Journal2014,,14:2
4Recent advances in engineered nanomaterials for acute kidney injury theranostics显示文摘Acute kidney injury(AKI),has become the focus of increasing attention due to its high risk of death.The early diagnosis and treatment of AKI significantly reduce the risk of renal tissue damage and kidney dysfunction.However,the efficient early diagnosis and treatment approach for AKI remains a challenge.AKI screening via precise nanomaterial theranostics is a new alternative approach.This study summarizes the recent advances in functional nanomaterials in the early detection and treatment of AKI.The challenges and problems in the use of nanomaterials for AKI in clinical applications are also discussed.It is anticipated that highlighting these new advances will lay the foundation for further translational research on the promising application of nanomaterials for AKI.Lefeng Wang Yunjing Zhang Yangyang Li Jianghua Chen Weiqiang Lin 2021Nano Research2021,14,4:1
5The Classification of hydrocarbons with factor analysis and the PONA analysis of gasoline显示文摘XIUHUA ZHU LEFENG ZHANG XUN CHE 1999Chemometrics and Intelligent Laboratory Systems1999,45,:1
6Twin peaks of in-hospital mortality among patients with STEMI across five phases of COVID-19 outbreak in China:a nation-wide study显示文摘Lockdown and re-opening may become cyclical due to the recurrent waves of the COVID-19 epidemic.Few studies have examined temporal trends and determinants of in-hospital mortality among patients with ST-segment elevation myocardial infarction(STEMI),a life-threatening condition that requires emergency medical care.Using nation-wide data before,during and after the Wuhan lockdown,we aimed to depict temporal patterns and major determinants of STEMI in-hospital mortality in China across five time periods of the COVID-19 epidemic.We analyzed the data of 283,661 STEMI patients who were admitted to 4,487 chest-pain-centers across China,from January 1,2019 to May 31,2020.Compared with the period before the lockdown,STEMI in-hospital mortality increased by 25%(OR 1.25,95%CI 1.16–1.34)during Early Lockdown,by 12%(OR 1.12,95%CI 1.03–1.22)during Later Lockdown,by 35%(OR 1.35,95%CI 1.21–1.50)during Early Lift,and returned to pre-COVID risk(OR 1.04,95%CI 0.95–1.14)during Later Lift.For each time-period,we observed a clear mortality gradient by timing and types of revascularization procedure.In conclusion,the COVID-19 epidemic had a significant adverse impact on STEMI in-hospital mortality,with bimodal peaks during early lockdown and early lift periods and clear mortality gradients by timing and types of revascularization procedure,independent of the time periods.Jianping Li Nan Zhang Ziyi Zhou Xiao Huang Weiyi Fang Hongbing Yan Jiyan Chen Weimin Wang Dingcheng Xiang Xi Su Bo Yu Yan Wang Yawei Xu Lefeng Wang Chunjie Li Kai Huang Xiaobin Wang Yong Huo Junbo Ge 2022Science China(Life Sciences)2022,65,9:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费